片頭痛治療の最前線
Saved in:
| Published in | 日本頭痛学会誌 Vol. 51; no. 4; pp. 680 - 682 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Japanese |
| Published |
一般社団法人 日本頭痛学会
2025
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1345-6547 2436-1577 |
| DOI | 10.50860/jjho.51.4_680 |
Cover
| Author | 石井, 亮太郎 |
|---|---|
| Author_xml | – sequence: 1 fullname: 石井, 亮太郎 organization: 京都府立医科大学大学院医学研究科脳神経内科学 |
| BookMark | eNo9j7tKA0EYRgeJ4BrT2vgMu84_92kECd4gYKP18M_ujNklJrKbxk5tJIW1eCl8AS1sLHwcMYtvoUGxOV9x4IOzSjrjyTgQsg40k9QoullVw0kmIRNOGbpEEia4SkFq3SEJcCFTJYVeIb2mKT2VRlhupU3IRju7_np6bm8f5q_v7d3Vx-XL_PHic3bTvt2vkeWIoyb0_rZLjnd3jvr76eBw76C_PUgr0AZTsMxYFgEoK8AbwGABedTcsAKVETRSyVWMiunCGy1QoM8hWCO0AZZ73iVbv79VM8WT4M7q8hTrc4f1tMxHwS3SnAQnFvip-xf5EGtXIf8GMhJTdw |
| ContentType | Journal Article |
| Copyright | 2025 一般社団法人日本頭痛学会 |
| Copyright_xml | – notice: 2025 一般社団法人日本頭痛学会 |
| DOI | 10.50860/jjho.51.4_680 |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2436-1577 |
| EndPage | 682 |
| ExternalDocumentID | article_jjho_51_4_51_680_article_char_ja |
| GroupedDBID | EIHBH JSF RJT |
| ID | FETCH-LOGICAL-j178a-192892f1102d1b81ae91a3f7382da6840f0536ff627db874a4abc1e9847812cb3 |
| ISSN | 1345-6547 |
| IngestDate | Thu Jul 17 14:00:39 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Issue | 4 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j178a-192892f1102d1b81ae91a3f7382da6840f0536ff627db874a4abc1e9847812cb3 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jjho/51/4/51_680/_article/-char/ja |
| PageCount | 3 |
| ParticipantIDs | jstage_primary_article_jjho_51_4_51_680_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2025 |
| PublicationDateYYYYMMDD | 2025-01-01 |
| PublicationDate_xml | – year: 2025 text: 2025 |
| PublicationDecade | 2020 |
| PublicationTitle | 日本頭痛学会誌 |
| PublicationTitleAlternate | 日頭痛会誌 |
| PublicationYear | 2025 |
| Publisher | 一般社団法人 日本頭痛学会 |
| Publisher_xml | – name: 一般社団法人 日本頭痛学会 |
| References | 18) Tassorelli C, Grazzi L, de Tommaso M, et al : Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. Neurology 91 : e364-e373, 2018. 2) Puledda F, Sacco S, Diener HC, et al : International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine. Cephalalgia 44 : 3331024241269735, 2024. 11) Ando K, Pegram BL, Frohlich ED : Hemodynamic effects of calcitonin gene-related peptide in spontaneously hypertensive rats. Am J Physiol 258 (2 Pt 2) : R425-429, 1990. 4) Amara SG, Jonas V, Rosenfeld MG, et al : Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298 : 240-244, 1982. 6) Wimalawansa SJ, Morris HR, Etienne A, et al : Isolation, purification and characterization of beta-hCGRP from human spinal cord. Biochem Biophys Res Commun 167 : 993-1000, 1990. 13) Portaluppi F, Vergnani L, Margutti A, et al : Modulatory effect of the renin-angiotensin system on the plasma levels of calcitonin gene-related peptide in normal man. J Clin Endocrinol Metab 77 : 816-820, 1993. 9) Brain SD, Williams TJ, Tippins JR, et al : Calcitonin gene-related peptide is a potent vasodilator. Nature 313 : 54-56, 1985. 20) Tepper SJ, Grosberg B, Daniel O, et al : Migraine treatment with external concurrent occipital and trigeminal neurostimulation-A randomized controlled trial. Headache 62 : 989-1001, 2022. 3) WHO Model List of Essential Medicines-23rd list, 2023［Internet］. World Health Organization ; 2023 Jul 26［cited 2025 Feb 6］. Available from : https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02 8) Lassen LH, Haderslev PA, Jacobsen VB, et al : CGRP may play a causative role in migraine. Cephalalgia 22 : 54-61, 2002. 16) Schoenen J, Vandersmissen B, Jeangette S, et al : Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 80 : 697-704, 2013. 5) Zaidi M, Bevis PJ, Girgis SI, et al : Circulating CGRP comes from the perivascular nerves. Eur J Pharmacol 117 : 283-284, 1985. 10) Wimalawansa SJ : Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 17 : 533-585, 1996. 19) Hershey AD, Lin T, Gruper Y, et al : Remote electrical neuromodulation for acute treatment of migraine in adolescents. Headache 61 : 310-317, 2021. 7) Mulderry PK, Ghatei MA, Bishop AE, et al : Distribution and chromatographic characterisation of CGRP-like immunoreactivity in the brain and gut of the rat. Regul Pept 12 : 133-143, 1985. 15) Ashina M, Terwindt GM, Al-Karagholi MA, et al : Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 397 : 1496-1504, 2021. 1) Puledda F, Sacco S, Diener HC, et al : International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia 44 : 3331024241252666, 2024. 17) Starling AJ, Tepper SJ, Marmura MJ, et al : A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study) . Cephalalgia 38 : 1038-1048, 2018. 12) Petersen KA, Birk S, Lassen LH, et al : The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 25 : 139-147, 2005. 14) Li J, Wang DH : Development of angiotensin Ⅱ-induced hypertension: role of CGRP and its receptor. J Hypertens 23 : 113-118, 2005. |
| References_xml | – reference: 3) WHO Model List of Essential Medicines-23rd list, 2023［Internet］. World Health Organization ; 2023 Jul 26［cited 2025 Feb 6］. Available from : https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02 – reference: 10) Wimalawansa SJ : Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 17 : 533-585, 1996. – reference: 17) Starling AJ, Tepper SJ, Marmura MJ, et al : A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study) . Cephalalgia 38 : 1038-1048, 2018. – reference: 6) Wimalawansa SJ, Morris HR, Etienne A, et al : Isolation, purification and characterization of beta-hCGRP from human spinal cord. Biochem Biophys Res Commun 167 : 993-1000, 1990. – reference: 2) Puledda F, Sacco S, Diener HC, et al : International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine. Cephalalgia 44 : 3331024241269735, 2024. – reference: 4) Amara SG, Jonas V, Rosenfeld MG, et al : Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298 : 240-244, 1982. – reference: 5) Zaidi M, Bevis PJ, Girgis SI, et al : Circulating CGRP comes from the perivascular nerves. Eur J Pharmacol 117 : 283-284, 1985. – reference: 7) Mulderry PK, Ghatei MA, Bishop AE, et al : Distribution and chromatographic characterisation of CGRP-like immunoreactivity in the brain and gut of the rat. Regul Pept 12 : 133-143, 1985. – reference: 12) Petersen KA, Birk S, Lassen LH, et al : The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 25 : 139-147, 2005. – reference: 11) Ando K, Pegram BL, Frohlich ED : Hemodynamic effects of calcitonin gene-related peptide in spontaneously hypertensive rats. Am J Physiol 258 (2 Pt 2) : R425-429, 1990. – reference: 1) Puledda F, Sacco S, Diener HC, et al : International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia 44 : 3331024241252666, 2024. – reference: 9) Brain SD, Williams TJ, Tippins JR, et al : Calcitonin gene-related peptide is a potent vasodilator. Nature 313 : 54-56, 1985. – reference: 15) Ashina M, Terwindt GM, Al-Karagholi MA, et al : Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 397 : 1496-1504, 2021. – reference: 19) Hershey AD, Lin T, Gruper Y, et al : Remote electrical neuromodulation for acute treatment of migraine in adolescents. Headache 61 : 310-317, 2021. – reference: 20) Tepper SJ, Grosberg B, Daniel O, et al : Migraine treatment with external concurrent occipital and trigeminal neurostimulation-A randomized controlled trial. Headache 62 : 989-1001, 2022. – reference: 16) Schoenen J, Vandersmissen B, Jeangette S, et al : Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 80 : 697-704, 2013. – reference: 18) Tassorelli C, Grazzi L, de Tommaso M, et al : Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. Neurology 91 : e364-e373, 2018. – reference: 8) Lassen LH, Haderslev PA, Jacobsen VB, et al : CGRP may play a causative role in migraine. Cephalalgia 22 : 54-61, 2002. – reference: 13) Portaluppi F, Vergnani L, Margutti A, et al : Modulatory effect of the renin-angiotensin system on the plasma levels of calcitonin gene-related peptide in normal man. J Clin Endocrinol Metab 77 : 816-820, 1993. – reference: 14) Li J, Wang DH : Development of angiotensin Ⅱ-induced hypertension: role of CGRP and its receptor. J Hypertens 23 : 113-118, 2005. |
| SSID | ssib058493959 ssib000994799 ssj0003321988 ssib050736135 |
| Score | 1.9785911 |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 680 |
| SubjectTerms | 抗CGRP 関連抗体 新規治療薬 片頭痛 |
| Title | 片頭痛治療の最前線 |
| URI | https://www.jstage.jst.go.jp/article/jjho/51/4/51_680/_article/-char/ja |
| Volume | 51 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 日本頭痛学会誌, 2025, Vol.51(4), pp.680-682 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07bxQxEF6dQkODQICAAEqBK7TH-bW2S-_hKEIKVSKlW3kfFmyRIHRpUiCgQSmoEY-CPwAFDQU_B5FT_gUz3r3TBqUIJ52sW-_M7HjHsj97PTNJ8kDK0ldCy9RTWOmgz3LqOavSCkOZ1LVuBEMH5-2n2daueLIn90aj08GppcNZOa6OzvUrWcWqUAd2RS_Z_7DsUihUwH-wL5RgYSgvZGPiFNGGwHreGWInxD7GGgO_nLiM5IzkeawBGkYcB9hIrMNbZopHHJyM7JErBzI7hKqRTBEre3o7Pe8pEi9tRpwg-RQkEKeJtUQvN18j7SbJeSSxxEi0an-ByoAEgSwgXIOGbrgP0Xkrxz4TOXTUGkod1VHImkcZoIvlsdEcH9GJz-3D1VoxGKq5kCmmTu5msljHBM9SKvvEMP343ge0fT7cvIiDddblkOrn_axLgvTvlAIANsNDmG377GAs6VgUS7YzYbr7TlAgXSFpIbAA0mJxA73oihag_CWmFMXTp9uv3ADpGjH4wAoonQPQWg61ABMNX4QBQpDBOUw1Mavq8j10IUmjvo_OaAvgqoWlxuKYYkROO1eTK_2SZ8N2Gl5LRq2_nqzPj9-dfv02__D55Mev-ce3v998P_ny-s_x-_nPTzeS3U23M91K-0QdaUuV9imsErRhAZAkq2mpqW8M9TworlntMZpQgKE-CyFjqi61El74sqKN0ejnzKqS30zW9g_2m1vJxkQ2ICR4amgQtAy6VEyHYDIWqjCZhNuJ6tpSvOiisRQXffF3VuZcTy5jh-823u4ma7OXh809gKKz8n404l8FomjX |
| linkProvider | ISSN International Centre |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E7%89%87%E9%A0%AD%E7%97%9B%E6%B2%BB%E7%99%82%E3%81%AE%E6%9C%80%E5%89%8D%E7%B7%9A&rft.jtitle=%E6%97%A5%E6%9C%AC%E9%A0%AD%E7%97%9B%E5%AD%A6%E4%BC%9A%E8%AA%8C&rft.au=%E7%9F%B3%E4%BA%95%2C+%E4%BA%AE%E5%A4%AA%E9%83%8E&rft.date=2025&rft.pub=%E4%B8%80%E8%88%AC%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E9%A0%AD%E7%97%9B%E5%AD%A6%E4%BC%9A&rft.issn=1345-6547&rft.eissn=2436-1577&rft.volume=51&rft.issue=4&rft.spage=680&rft.epage=682&rft_id=info:doi/10.50860%2Fjjho.51.4_680&rft.externalDocID=article_jjho_51_4_51_680_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1345-6547&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1345-6547&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1345-6547&client=summon |